Intellective Biologics (Suzhou) Co., Ltd.

智享生物（苏州）股份有限公司

Provides biologics CDMO services in China, covering process development through commercial manufacturing of biologics, including therapeutic antibodies. Ranked second among China biologics CDMOs by number of commercial products and third in therapeutic antibodies by revenue in 2025, per Frost & Sullivan.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Customer concentration
• Supplier concentration
• Overlapping customers and suppliers
• Capacity and utilisation
• Losses and path to profitability
• Working capital: receivables, prepayments and cash cycle
• Inventory level and ageing
• Preferred shares and fair-value liabilities
• Investments and fair-value assets
• Indebtedness, guarantees and other contingent obligations
• Non-IFRS measures and adjustments